Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Subscribe To Our Newsletter & Stay Updated
